Prof. Senem KARABULUT

Publication Network

Journal articles indexed in SCI, SSCI, and AHCI

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Tasci E. S., Oyan B., Soenmez O., Mutlu A. U., Atci M. M., Sakin A., et al.

BMC CANCER , vol.24, no.1, 2024 (SCI-Expanded)

Evaluating complete response prediction rates in locally advanced rectal cancer with different radiomics segmentation approaches.

Kaval G., Dagoglu Kartal M. G., Azamat S., Cingoz E., Ertas G., Karaman S., et al.

Pathology oncology research : POR , vol.30, pp.1611744, 2024 (SCI-Expanded)

Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study

DEMİRCİ N. S., AZİZY A., Paksoy N., Doǧan I., KARABULUT S., Karahan L., et al.

Medicine (United States) , vol.103, no.9, 2024 (SCI-Expanded) Sustainable Development

Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer

KARABULUT S., ŞEN S., OĞUZ SOYDİNÇ H., Dogan I., TAŞTEKİN D., Karabulut M., et al.

PATHOLOGY RESEARCH AND PRACTICE , vol.254, 2024 (SCI-Expanded) Sustainable Development

Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?

Karabulut S., Afsar C. U., Paksoy N., Ferhatoglu F., Dogan I., Tastekin D.

Journal of cancer research and therapeutics , 2024 (SCI-Expanded)

Disease characteristics and prognostic factors of colorectal cancer patients with bone metastasis: A real-world data from Turkey.

Karabulut S., Afsar C. U., Khanmammadov N., Karahan L., Paksoy N., Dogan I., et al.

Journal of cancer research and therapeutics , 2024 (SCI-Expanded) Sustainable Development

The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , vol.36, no.7, pp.613-621, 2024 (SCI-Expanded) Sustainable Development

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.

The oncologist , vol.28, no.10, pp.875-884, 2023 (SCI-Expanded)

SERUM FETUIN-A AND RANKL LEVELS IN PATIENTS WITH EARLY STAGE BREAST CANCER SERUM FETUIN-A I NIVOI RANKLA KOD PACIJENATA SA RANIM STADIJOM RAKA DOJKE

Afsar C. U., Aral H., Can O., Trabulus D. C., Karacetin D., Nazlı M. A., et al.

Journal of Medical Biochemistry , vol.42, no.2, pp.249-257, 2023 (SCI-Expanded)

Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience

TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., et al.

Journal of cancer research and therapeutics , vol.19, no.2, pp.253-258, 2023 (SCI-Expanded) Sustainable Development

Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up : FDG PET in recurrent colorectal CA.

ozkan Z. G., Has Simsek D., Kuyumcu S., Oflas M., Isik E. G., Dogan I., et al.

Annals of nuclear medicine , vol.36, no.1, pp.52-60, 2022 (SCI-Expanded) Sustainable Development

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., et al.

Turkish Journal of Medical Sciences , vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded)

Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study

Karabulut S., Dogan I., Usul Afsar C., Karabulut M., Karaman S., Ferhatoglu F., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.27, no.6, pp.1357-1363, 2021 (SCI-Expanded) Sustainable Development

A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.

Yekeduz E., Dogan I., AKBULUT H., Karabulut S., Utkan G., ÜRÜN Y.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3, 2021 (SCI-Expanded) Sustainable Development

CLINICAL UTILITY OF TENSIN 2 LEVELS AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN BREAST CANCER

SERİN K. R., Ucuncu Z., TEMEL M. K., BADEMLER S., Soydinc H. O., KARANLIK H., et al.

ACTA MEDICA MEDITERRANEA , vol.37, no.1, pp.553-558, 2021 (SCI-Expanded) Sustainable Development

Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.

Dogan I., Tastekin D., Karabulut S., Sakar B.

JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.3, 2021 (SCI-Expanded)

Circulating annexin A2 as a biomarker in patients with pancreatic cancer.

Karabulut M., Afsar C. U., Serilmez M., Karabulut S.

Journal of cancer research and therapeutics , vol.16, 2020 (SCI-Expanded) Sustainable Development

Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., et al.

JOURNAL OF BUON , vol.25, no.4, pp.1897-1903, 2020 (SCI-Expanded)

Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT

Arslan E., Aral H., Aksoy T., Afsar C. U., Karabulut S., Trabulus F. D. C., et al.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA , vol.66, no.5, pp.673-679, 2020 (SCI-Expanded) Sustainable Development

The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer

Ucuncu M., Serilmez M., Sari M., Bademler S., Karabulut S.

BIOMOLECULES , vol.9, no.9, 2019 (SCI-Expanded) Sustainable Development

Serum IL-17 levels can be diagnostic for gastric cancer.

Karabulut M., Afsar C. U., Serimez M., Karabulut S.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.24, no.4, pp.1601-1609, 2019 (SCI-Expanded) Sustainable Development

Clinical significance of serum membrane-bound mucin-2 levels in breast cancer

Bademler S., ZİRTİLOĞLU A., Sari M., Ucuncu M. Z., Dogru E., Karabulut S.

Biomolecules , vol.9, no.2, 2019 (SCI-Expanded) Sustainable Development

IGF-1 AND IGFBP-3 IN COLORECTAL CANCER, AN OBSERVATIONAL CASE-CONTROL STUDY

Bademler S., ZİRTİLOĞLU A., Sari M., Yasasever C., Karabulut S.

ACTA MEDICA MEDITERRANEA , vol.35, no.1, pp.15-21, 2019 (SCI-Expanded) Sustainable Development

Clinical significance of serum caveolin-1 levels in gastric cancer patients.

Tas F., Karabulut S., Erturk K., Duranyildiz D.

Experimental oncology , vol.40, pp.323-327, 2018 (SCI-Expanded) Sustainable Development

Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

Afsar C. U., Karabulut M., Karabulut S., Ozal S. T., Cikot M., Serilmez M., et al.

BIOMOLECULES , vol.8, no.4, 2018 (SCI-Expanded) Sustainable Development

Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study

Korkmaz L., COŞKUN H. Ş., DANE F., KARABULUT B., Karaagac M., ÇABUK D., et al.

SURGICAL ONCOLOGY-OXFORD , vol.27, no.3, pp.485-489, 2018 (SCI-Expanded) Sustainable Development

Clinical significance of serum leptin level in patients with gastric cancer

Tas F., Karabulut S., Erturk K., Duranyildiz D.

EUROPEAN CYTOKINE NETWORK , vol.29, no.2, pp.52-58, 2018 (SCI-Expanded) Sustainable Development

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer

BADEMLER S., Sari M., Üçüncü M. Z., SERİLMEZ M., Karabulut S.

Acta Medica Mediterranea , vol.34, no.6, pp.2055-2060, 2018 (SCI-Expanded) Sustainable Development

Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

Afsar C. U., Karabulut M., Karabulut S., Alis H., Gonenc M., Dagoglu N., et al.

JOURNAL OF INFECTION AND CHEMOTHERAPY , no.4, pp.196-200, 2017 (SCI-Expanded) Sustainable Development

Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients

Tas F., Karabulut S., Guveli H., Kurul S., Erturk K., Guveli M., et al.

Asian Pacific journal of cancer prevention : APJCP , vol.18, pp.369-373, 2017 (SCI-Expanded)

THE EFFECT OF PRETREATMENT NEUTROPHIL/LEUCOCYTE RATIO ON SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL CANCER RECEIVING CHEMORADIOTHERAPY

Karaca F., Afsar C. U., Almalı N., KARABULUT S., Karabulut M., Keskin S., et al.

ACTA MEDICA MEDITERRANEA , vol.33, no.6, pp.905-911, 2017 (SCI-Expanded) Sustainable Development

SERUM INTERLEUKIN-32 (IL-32) LEVELS MAY HAVE DIAGNOSTIC AND PROGNOSTIC ROLES IN PATIENTS WITH PANCREATIC ADENOCARCINOMA

Karabulut M., Afsar C. U., Karabulut S., Peker K. D., Gemici E., Dagoglu N., et al.

ACTA MEDICA MEDITERRANEA , no.4, pp.613-619, 2017 (SCI-Expanded) Sustainable Development

CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1/CCL-2) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA

Afsar C. U., Karabulut M., Karabulut S., Alis H., Binboga S., Bilgin E., et al.

ACTA MEDICA MEDITERRANEA , vol.33, no.3, pp.501-507, 2017 (SCI-Expanded) Sustainable Development

Clinical significance of serum interleukin-17 levels in colorectal cancer patients

Karabulut S., Afsar C. U., Karabulut M., Kilic L., Alis H., Kones O., et al.

JOURNAL OF BUON , vol.21, no.5, pp.1137-1145, 2016 (SCI-Expanded) Sustainable Development

Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy.

Karabulut S., AFSAR C. U., KARABULUT M., ALIS H., Erturk K., Karaman S., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , vol.21, no.4, pp.895-902, 2016 (SCI-Expanded)

Clinical significance of serum caveolin-1 levels in melanoma patients

Tas F., Karabulut S., Yasasever C. T., Duranyildiz D.

INTERNATIONAL JOURNAL OF DERMATOLOGY , vol.55, no.5, pp.558-562, 2016 (SCI-Expanded) Sustainable Development

Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma.

KARABULUT M., GUNALDI M., ALIS H., AFSAR C., KARABULUT S., Serilmez M., et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico , vol.18, pp.160-71, 2016 (SCI-Expanded)

CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-A) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH PANCREATIC ADENOCARCINOMA

Karabulut S., Afsar C. U., Karabulut M., Alis H., Binboga S., Ozkara I. O., et al.

ACTA MEDICA MEDITERRANEA , vol.32, no.4, pp.1035-1040, 2016 (SCI-Expanded) Sustainable Development

Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation

ERDOĞAN B., Kodaz H., Karabulut S., Cinkaya A., TOZKIR H., TANRIVERDİ Ö., et al.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES , vol.16, no.4, pp.280-285, 2016 (SCI-Expanded) Sustainable Development

Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer

Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.77, no.1, pp.127-131, 2016 (SCI-Expanded) Sustainable Development

CLINICAL SIGNIFICANCE OF SERUM HEPATOCYTE GROWTH FACTOR (HGF) AND ITS RECEPTOR CMET LEVELS IN COLORECTAL CANCER PATIENTS

KARABULUT M., ALIS H., GUNALDI M., AFSAR C. U., Karabulut S., KONES O., et al.

ACTA MEDICA MEDITERRANEA , vol.32, no.1, pp.179-187, 2016 (SCI-Expanded) Sustainable Development

Tongue metastasis of melanoma

Tas F., Karabulut S., Yegen G., Onder S., Ciftci R.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.11, no.3, 2015 (SCI-Expanded)

Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer

KARABULUT M., ALIS H., AFSAR C. U., Karabulut S., KOCATAS A., Oguz H., et al.

BIOMEDICINE & PHARMACOTHERAPY , vol.73, pp.140-146, 2015 (SCI-Expanded) Sustainable Development

Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine , vol.36, no.3, pp.2097-103, 2015 (SCI-Expanded) Sustainable Development

Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

BIOMEDICINE & PHARMACOTHERAPY , vol.70, pp.19-23, 2015 (SCI-Expanded) Sustainable Development

Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer

Tas F., Bilgin E., Karabulut S., Duranyildiz D.

CYTOKINE , vol.71, no.1, pp.66-70, 2015 (SCI-Expanded) Sustainable Development

Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Biomedicine and Pharmacotherapy , vol.69, pp.237-241, 2015 (SCI-Expanded) Sustainable Development

D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.

Kilic L., Yildiz I., Sen F. K., ERDEM M. G., Serilmez M., Keskin S., et al.

Cancer biomarkers : section A of Disease markers , vol.15, no.4, pp.405-11, 2015 (SCI-Expanded) Sustainable Development

Combination of Capecitabine and Phenytoin May Cause Phenytoin Intoxication: A Case Report

Ciftci R., Tas F., Karabulut S., CIFTCI S.

AMERICAN JOURNAL OF THERAPEUTICS , vol.22, no.1, 2015 (SCI-Expanded) Sustainable Development

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer

Tas F., Karabulut S., Duranyildiz D.

MOLECULAR AND CELLULAR BIOCHEMISTRY , vol.396, pp.307-312, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum fibronectin and vitronectin levels in melanoma patients

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

MELANOMA RESEARCH , vol.24, no.5, pp.475-479, 2014 (SCI-Expanded)

Clinical significance of serum M30 and M65 levels in patients with breast cancer

Tas F., Karabulut S., Yildiz I., Duranyildiz D.

BIOMEDICINE & PHARMACOTHERAPY , vol.68, no.8, pp.1135-1140, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.9, pp.9303-9309, 2014 (SCI-Expanded) Sustainable Development

Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy

Tas F., Karabulut S., Bilgin E., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.8, pp.7871-7875, 2014 (SCI-Expanded) Sustainable Development

The Behavior of Turkish Cancer Patients in Fasting During the Holy Month of Ramadan

Tas F., Karabulut S., Ciftci R., Yildiz I., Keskin S., Kilic L., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.44, no.8, pp.705-710, 2014 (SCI-Expanded) Sustainable Development

Serum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma

Tas F., Karabulut S., Yasasever C., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.7, pp.7233-7237, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer.

Varol B., ÇOŞKUN Ö., Karabulut S., SERIN K. R., Asoglu O., Albeniz I., et al.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine , vol.35, no.6, pp.5575-82, 2014 (SCI-Expanded) Sustainable Development

Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6, pp.1163-1171, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.4, pp.3125-3132, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum transforming growth factor-beta 1 (TGF-beta 1) levels in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.4, pp.3611-3616, 2014 (SCI-Expanded) Sustainable Development

Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.4, pp.3327-3331, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , vol.35, no.4, pp.3095-3102, 2014 (SCI-Expanded) Sustainable Development

Recurrent gastric cancer presenting with both scrotal and facial skin metastases: a case report.

Tas F., Ciftci R., Buyukbabani N., Karabulut S.

Journal of gastrointestinal cancer , vol.45, pp.96-9, 2014 (SCI-Expanded) Sustainable Development

Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3, pp.631-637, 2014 (SCI-Expanded) Sustainable Development

High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer

Ciftci R., Tas F., Yasasever C., Aksit E., Karabulut S., Sen F., et al.

Tumor Biology , vol.35, no.7, pp.6941-6948, 2014 (SCI-Expanded) Sustainable Development

Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., et al.

TUMOR BIOLOGY , vol.34, no.6, pp.3529-3536, 2013 (SCI-Expanded)

Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.

Tas F., Karabulut S., Bilgin E., Kılıc L., Cıftcı R., Duranyıldız D.

Journal of gastrointestinal cancer , vol.44, pp.404-9, 2013 (SCI-Expanded)

Age is a prognostic factor affecting survival in lung cancer patients

Tas F., Ciftci R., Kilic L., Karabulut S.

ONCOLOGY LETTERS , vol.6, no.5, pp.1507-1513, 2013 (SCI-Expanded) Sustainable Development

The role of surgical methods in the treatment of anorectal malignant melanoma (AMM).

Keskin S., Tas F., Karabulut S., Yildiz I., Kiliç L., Ciftci R., et al.

Acta chirurgica Belgica , vol.113, pp.429-33, 2013 (SCI-Expanded)

Clinical significance of serum M30 and M65 levels in melanoma

Tas F., Karabulut S., Serilmez M., Yildiz I., Sen F., Ciftci R., et al.

MELANOMA RESEARCH , vol.23, no.5, pp.390-395, 2013 (SCI-Expanded)

Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

Aykan N. F., Yildiz I., Sen F., Kilic L., Keskin S., Ciftci R., et al.

MEDICAL ONCOLOGY , vol.30, no.3, 2013 (SCI-Expanded) Sustainable Development

Clinical and prognostic significance of coagulation assays in gastric cancer.

Tas F., Ciftci R., Kilic L., Serilmez M., Karabulut S., Duranyildiz D.

Journal of gastrointestinal cancer , vol.44, pp.285-92, 2013 (SCI-Expanded) Sustainable Development

A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

Yildiz I., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.72, no.2, pp.437-444, 2013 (SCI-Expanded) Sustainable Development

Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.

Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz I., et al.

Tumori , vol.99, no.4, pp.463-8, 2013 (SCI-Expanded) Sustainable Development

Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?

Aydiner A., Ciftci R., Karabulut S., Kilic L.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.14, no.10, pp.6109-6114, 2013 (SCI-Expanded) Sustainable Development

Articles Published in Other Journals

Comparison of Clinical Outcomes in Locally Advanced Distal Rectal Cancer Patients with Complete Clinical Response: Total Mesorectal Excision versus Nonoperative Management

KULLE C. B., KESKİN M., SELÇUKBİRİCİK F., KARABULUT S., SEZEN D., KARAMAN Ş., et al.

World Journal of Colorectal Surgery , vol.13, 2024 (Peer-Reviewed Journal)

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study

Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, no.4, pp.478-483, 2022 (ESCI)

Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers

Karabulut S., Topalgokceli M. S., Tastekin D.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.6, no.1, pp.12-15, 2022 (ESCI) Sustainable Development

WHAT'S NEW IN METASTATIC COLON CANCER TREATMENT?

Karabulut S., Karabulut M., Tastekin D.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.84, no.3, pp.425-429, 2021 (ESCI) Sustainable Development

Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study.

Yekedüz E., Doğan İ., Birgi S. D., Keskin M., Karaman Ş., Utkan G., et al.

Euroasian journal of hepato-gastroenterology , vol.11, no.2, pp.51-58, 2021 (Peer-Reviewed Journal)

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

ARTAÇ M., Korkmaz L., COŞKUN H. Ş., DANE F., KARABULUT B., KARAAĞAÇ M., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.50, no.2, pp.214-220, 2019 (ESCI) Sustainable Development

The Association of Pancreatic Cancer and PALB2 Gene Mutations in the Turkish Population

Turkcan G. K., Odemis D., Avsar M., Tuncer S. B., Erciyas S., Erdogan Ö., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.34, no.4, pp.283-290, 2019 (ESCI)

Serum Glypican-3, Vascular Endothelial Growth Factor, and lnterleukin-6 Levels in Hepatocellular Carcinoma

Serilmez M., Akyuz F., Ormeci Ciftcibasi A., Karabulut S., Kaymakoglu S., Yasasever V., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.33, no.1, pp.18-27, 2018 (ESCI)

Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer.

KARABULUT M., AFSAR C., ALıS H., ORAN E., KARABULUT S., AKARSU C., et al.

Molecular and clinical oncology , vol.7, pp.787-797, 2017 (ESCI) Sustainable Development

Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience

Kilic L., Ekenel M., Karabulut S., Agaoglu F., Darendeliler E.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY , vol.21, no.1, pp.60-65, 2017 (ESCI)

Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma

Karabulut S., Afsar C. U., Karabulut M., Alis H., Bozkurt M. A., Aydogan F., et al.

BBA CLINICAL , vol.6, pp.138-142, 2016 (ESCI) Sustainable Development

Benefit of Bevacizumab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study

ARTAÇ M., COŞKUN H. Ş., DANE F., KARABULUT B., KORKMAZ L., KARAAĞAÇ M., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.47, no.3, pp.264-272, 2016 (Scopus)

Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients

Tas F., Bılgın E., Karabulut S., Duranyıldız D.

MOLECULAR AND CLINICAL ONCOLOGY , vol.5, no.1, pp.195-200, 2016 (ESCI)

Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma

Tas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D.

BBA CLINICAL , vol.5, pp.166-169, 2016 (ESCI) Sustainable Development

Pankreas Adenokanserli Hastalarda Serum Transforme Edici Büyüme Faktör Beta-1 (TGF B1) Düzeyleri

KARABULUT S., KARABULUT M., USUL AFŞAR Ç., ALIŞ H., DAĞOĞLU SAKİN R. N., AKARSU C., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.12, no.1, pp.24-32, 2016 (Peer-Reviewed Journal)

Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients

Tas F., Karabulut S., Tastekin D., Duranyildiz D.

BIOMEDICAL REPORTS , vol.4, no.4, pp.489-492, 2016 (ESCI) Sustainable Development

Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome

Tas F., Bılgın E., Karabulut S., Tastekın D., Duranyıldız D.

MOLECULAR AND CLINICAL ONCOLOGY , vol.4, no.4, pp.655-659, 2016 (ESCI) Sustainable Development

Pankreas adenokarsinomlu hastalarda serum transforme edici büyüme factor beta 1 TGF B1 düzeyleri

KARABULUT S., KARABULUT M., AFŞAR USUL Ç., ALIŞ H., DAĞOĞLU N., AKARSU C., et al.

İstanbul Tıp Fakültesi Dergisi , vol.79, no.1, pp.9-15, 2016 (Peer-Reviewed Journal)

Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma

KARABULUT S., Afsar Ç. U., Karabulut M., Alış H., Kılıc L., Çikot M., et al.

Journal of Gastrointestinal Cancer , vol.47, no.1, pp.47-54, 2016 (Scopus)

SERUM TRANSFORMING GROWTH FACTOR BETA 1 (TGF-B1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS

Karabulut S., Karabulut M., Usul Afsar C., Alis H., Dagoglu N., Akarsu C., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , no.1, pp.9-15, 2016 (ESCI) Sustainable Development

Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high risk extremity soft tissue sarcoma A single institution experience

KILIÇ L., EKENEL M., KARABULUT S., AĞAOĞLU F., DARENDELİLER M. E.

WSPOLCZESNA ONKOLOGIA , 2016 (Scopus)

Pankreas adenokanserli hastalarda serum ekstrasellülermatriks proteinlerininprognostik ve prediktif değerinin araştırılması

KARABULUT S., KARABULUT M., ALIŞ H., DAĞOĞLU R. N., TAMBAŞ M., KAPAN S., et al.

MEDICAL JOURNAL OF BAKIRKOY , vol.12, no.1, pp.24-32, 2016 (Scopus)

Is serum tenascin-C level potential biomarker in pancreatic adenocarcinoma?

Karabulut S., KARABULUT M., ALIS H., Tambas M., KAPAN S., KONES O., et al.

MEDICAL JOURNAL OF BAKIRKOY , vol.12, no.2, pp.76-82, 2016 (ESCI)

The predictive and prognostic value evaluation of serum extracellular matrix proteins levels in patients with pancreas adenocarcinoma

Karabulut S., KARABULUT M., ALIS H., Dagoglu N., Tambas M., KAPAN S., et al.

MEDICAL JOURNAL OF BAKIRKOY , no.1, pp.24-32, 2016 (ESCI) Sustainable Development

PANKREATİK ADENOKANSERDE SİRKÜLASYONDAKİ PROİNFLAMATUAR SİTOKİN DÜZEYLERİNİN KLİNİK ÖNEMİ

KARABULUT S., KARABULUT M., USUL AFŞAR Ç., Alış H., GÜVELİ M. E., Ünsal M. G., et al.

İSTANBUL TIP FAKÜLTESİ DERGİSİ , vol.78, no.4, pp.102-109, 2015 (Peer-Reviewed Journal)

Clinical significance of serum claudin-1 and claudin-7 levels in patients with colorectal cancer

Karabulut M., Alis H., Bas K., Karabulut S., Afsar C. U., Oguz H., et al.

MOLECULAR AND CLINICAL ONCOLOGY , vol.3, no.6, pp.1255-1267, 2015 (ESCI) Sustainable Development

CLINICAL SIGNIFICANCE OF CIRCULATING PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA

Karabulut S., Karabulut M., Afsar C. U., Alis H., Guveli M. E., Unsal M. G., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.78, no.4, pp.102-109, 2015 (ESCI)

To investigate possible etiologic factors of organic and functional dyspepsia in Turkey

KARABULUT S., Karabulut M., Akarsu C., Bozkurt M. A., BADEMLER S., Kocatas A., et al.

MEDICAL JOURNAL OF BAKIRKOY , vol.11, no.1, pp.17-23, 2015 (ESCI)

Türk toplumunda organik ve fonksiyonel dispepsili hastalarda etyolojiye yönelik analiz.

KARABULUT S., KARABULUT M., AKARSU C., BOZKURT M. A., BADEMLER S., KOCATAŞ A., et al.

BAKIRKÖY TIP DERGİSİ , no.11, pp.17-23, 2015 (Scopus)

Sunitinib ile tedavi edilen metastatik böbrek hücreli karsinom hastalarının klinik olarak değerlendirilmesi: Tek merkez deneyimi

KARABULUT S., EKENEL M., IRIBAS A., DARENDELILER E., BAŞARAN M., BAVBEK S. E.

TÜRK ONKOLOJİ DERGİSİ , vol.30, pp.51-60, 2015 (Scopus)

Clinical evaluation of sunitinib in patients with metastatic renal cell carcinoma: Single center experience

Karabulut S., Ekenel M., Iribas A., Darendeliler E., Basaran M., Bevbek S.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.30, no.2, pp.51-60, 2015 (ESCI)

Endometrium Kanserinde Kemoterapi

KARABULUT S., SAİP P. M.

Türkiye Klinikleri Jinekoloji Obstetrik , vol.7, no.3, pp.100-106, 2014 (Peer-Reviewed Journal) Sustainable Development

The Frequencies of Breast Cancer BC in Extreme Ages Changing Over Time

KESKİN S., ÇİFTÇİ R., KARABULUT S., KÜÇÜÇÜK S., YILDIZ İ., KILIÇ L., et al.

Mediterranean Oncology Journal , vol.1, pp.46-19, 2012 (Peer-Reviewed Journal) Sustainable Development

Papers Presented at Peer-Reviewed Scientific Conferences

Kolorektal Kanser Tanılı Hastalarda Sağkalımı Öngörmede Florodeoksiglukoz Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi ve Serum Karsinoembriyojenik Antijen Değerinin Rolü

OFLAS M., HAS ŞİMŞEK D., IŞIK E. G., KIRAN M. Y., DOĞAN İ., KARABULUT S., et al.

32. ULUSAL NÜKLEER TIP KONGRESİ, Turkey, 20 - 21 November 2020, vol.6, pp.16-17, (Summary Text)

Comparison of serum NEDD 9, CA 15-3 and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT

Arslan E., Aral H., Aksoy T., Afsar C. U., Karabulut S., Trabulus F. C., et al.

SNMMI Annual Meeting, ELECTR NETWORK, 11 - 14 July 2020, vol.61, (Summary Text) Sustainable Development

Does nutritional status affect treatment tolarability, response, and survival in metastatic colorectal cancer patients? Results of prospective multicenter study

Karabulut S., Dogan I., Afsar C. U., Karabulut M., Karaman S., Ferhatoglu F., et al.

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica, 23 - 25 January 2020, vol.38, (Summary Text) Sustainable Development

Short-term outcomes of non-operative management in locally advanced distal rectal cancer patients after consolidation FOLFOX chemoradiotherapy: single center experience

Kulle C. B., Özgür I., Keskin M., Karaman Ş., Karabulut S., Dağoğlu Kartal M. G., et al.

ESCP Vienna 2019, 14th Scientific and Annual Meeting, 25-27 September 2019 Vienna, Austria, Vienna, Austria, 25 - 27 September 2019, vol.21, no.3, pp.33-128, (Full Text)

Bipolar Hastalarda Nöroinflamasyon ve Nöronal Yıkım Belirteçlerinin Farklı Hastalık Alt Gruplarında Karşılaştırmalı İncelenmesi

Akcan U., Karabulut S., KÜÇÜKALİ C. İ., Çakır S., Tüzün E.

15. Ulusal Sinirbilim Kongresi, Sakarya, Turkey, 7 - 10 May 2017, (Full Text)

Inflammation and neurodegeneration findings in early stage bipolar disorder

Karabulut S., Akcan U., KÜÇÜKALİ C. İ., Tüzün E., Çakır S.

25th European Congress of Psychiatry, Floransa, Italy, 1 - 04 April 2017, vol.41, no.1, (Full Text)

Frequency of Large Deletions and Duplications in the BRCA1/2 Genes in Turkish High Risk Breast and Ovarian Cancer Cases

AKDENİZ ÖDEMİŞ D., ŞÜKRÜOĞLU ERDOĞAN Ö., KILIÇ S., TUNÇER Ş. B., AVŞAR M., KURU G., et al.

International Breastanbul Conference, İstanbul, Turkey, 10 - 12 November 2016, pp.7, (Full Text) Sustainable Development

Circulating interleukin-18 (IL-18) as a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.

Afsar C. U., Karabulut M., KARABULUT S., Tuna S., Alis H., Gonenc M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text)

Diagnostic and prognostic roles of serum interleukin-32 (IL-32) levels in patients with pancreatic adenocarcinoma.

KARABULUT S., Afsar C. U., Yasasever V., Karabulut M., Erturk K., Alis H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text)

Metastatik hormona dirençli prostat kanserinde abirateron deneyimiz

KARABULUT S., EKENEL M., ÇİFTÇİ R., ÇELEBİ K., İRİBAŞ A., DARENDELİLER M. E., et al.

Avrasya Üronkoloji Bahar Kongresi, Bursa, Turkey, 28 April - 01 May 2016 Sustainable Development

Birinci basamak bevasizumab bazlı tedaviler kullanan metastatic kolorektal kanserli hastalarda primer tümörün rezeksiyonunun prognostic önemi Türk Onkoloji Grubu Çalışması

KORKMAZ L., COŞKUN H. Ş., DANE F., KARABULUT B., KARAAĞAÇ M., ÇABUK D., et al.

6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016 Sustainable Development

Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?

Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text) Sustainable Development

Prognostic roles of serum NEDD9 levels in patients with gastric cancer.

Karabulut S., Karabulut M., Alis H., Bozbey H. U., Sakar B., Vatansever S., et al.

Clinical significance of serum claudin-7 levels in patients with colorectal cancer.

Aydogan F., Karabulut M., Alis H., Karabulut S., Celebi K., Bozbey H. U., et al.

Metastatik kastrasyona dirençli prostat kanserinde abireteron deneyimimiz

EKENEL M., ÇİFTÇİ R., KARABULUT S., ÇELEBİ K., IRIBAS A., DARENDELİLER E., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text) Sustainable Development

Trombozu olan metastatik böbrek hücreli tümörlerde sunitinib tedavisinin sonuçları

EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text)

Kolorektal Kanser Tespitinde Serum İnterlökin-17 (Il-17) Seviyelerinin Diagnostik Değeri Var Mıdır?

ERTÜRK K., KARABULUT M., ALIS H., GÜNALDI M., KARABULUT S., ÇELEBİ K., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1, (Full Text) Sustainable Development

Serum NEDD9 Seviyeleri Gastrik Kanserli Hastalarda Prognostik Rolü

GÜNALDI M., KARABULUT M., ALIS H., KARABULUT S., KİZİR A., OĞUZ SOYDİNÇ H., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1, (Full Text) Sustainable Development

Metastatik böbrek hücreli tümörlerde sunitinib sonrası everolimus etkinliği

EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.553, (Full Text)

Sunitinib ile tedavi edilen metastatik renal hücreli karsinom (MRHK)hasta sonuçları, tek merkez deneyimi

EKENEL M., KARABULUT S., YILDIZ İ., IRIBAS A., DARENDELİLER E., BAŞARAN M., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.256, (Full Text)

Yüksek vücut kitle indeksi (VKİ)hedefe yönelik tedavi alan metastatik renal hücreli karsinom (BHK) hastalarında daha iyi sağkalımı öngörüyor mu?

KARABULUT S., EKENEL M., YILDIZ I., IRIBAS A., DARENDELİLER E., BAŞARAN M., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552, (Full Text)

Kolorektal Kanserli Hastalarda Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Seviyelerinin Değerlendirilmesi ve Klinikopatolojik Özelliklerle Olan Korelasyonu

KARABULUT S., ALIS H., KARABULUT M., GÜNALDI M., OĞUZ SOYDİNÇ H., ERTÜRK K., et al.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1, (Full Text) Sustainable Development

Distribution and frequency of BRCA gene mutations in Turkish population including Balkan Turks

AKDENIZ D., Tuncer B. S., kılıç S., şükrüoğlu O., Kilic L., ALTUNDAĞ K., et al.

AACR Special Conference on Cancer Susceptibility and Cancer Susceptibility Syndromes, California, United States Of America, 29 January - 01 February 2014, vol.74, (Summary Text)

The diagnostic, predictive, and prognostic role of serum cellular adhesion molecules (VCAM-1, EpCAM) levels in breast cancer patients

Aykan N. F., Karabulut S.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32 Sustainable Development

Clinical significance of serum transforming growth factor beta 1 (TGFB1) level in breast cancer.

CIFTCI R., Tas F., Kilic L., Vatansever S., KARABULUT S.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text) Sustainable Development

Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.

CIFTCI R., Tas F., AKSIT E., Vatansever S., KARABULUT S., Sen F., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text) Sustainable Development

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) cud vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.

KARABULUT S., Tastekin D., CIFTCI R., Tambas M., DAGOGLU N., Guveil M. E., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text) Sustainable Development

Clinical significance of serum caveolin-1 levels in melanoma.

Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)

Kalıtsal meme kanser hastalarında saptanan BRCA1 2 gen mutasyonlarının bölgesel ve etnik dağılımı ile klinik özellikleri

AKDENİZ ÖDEMİŞ D., TUNCER B., KILIÇ S., ŞÜKRÜOĞLU Ö., ALTUNDAĞ K., KILIÇ L., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014 Sustainable Development

Epitelyal Over Kanserinin Belirlenmesi Üzerinde Protease Activated Receptor-1(PAR-1) Düzeylerinin Herhangi Bir Tanısal Değeri Var Mıdır?

Karabulut S., Ciftci R., Vatansever S., TAŞ F., TİLGEN YASASEVER C., YASASEVER F. V., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421, (Full Text) Sustainable Development

Epitelyal Over Kanserli Hastalarda Yüksek Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Düzeyleri Kötü Progresyonsuz Sağkalımla İlişkilidir

Karabulut S., Ciftci R., Tastekin D., TİLGEN YASASEVER C., VATANSEVER S., Duranyildiz D., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.428, (Full Text) Sustainable Development

Akciğer Karsinomlu Hatalarda VCAM-1 ve EPCAM Serum Konsantrasyonlarının Klinik Önemi

Tastekin D., Karabulut S., TAŞ F., Ciftci R., TİLGEN YASASEVER C., DURANYILDIZ H. D.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.572, (Full Text)

Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi

Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TİLGEN YASASEVER C., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421, (Full Text) Sustainable Development

Meme Kanserli Hstalarda Serum MIF (Macrophage Migration Inhibitory Factor) Düzeylerinin Klinik Açıdan Önemi

Ciftci R., Karabulut S., TİLGEN YASASEVER C., Aksit E., Yildiz I., BİLGİN DOĞRU E., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.501, (Full Text) Sustainable Development

Serum Hücresel Adhezyon Molekülleri (VCAM-1, EPCAM) Seviyelerinin Meme Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü

Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., Aydiner A., TİLGEN YASASEVER C., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.493, (Full Text) Sustainable Development

Kalıtsal meme kanseri hastalarında saptanan BRCA1/2 gen mutasyonlarının bölgesel ve etnik dağılımları ile klinik özellikleri

AKDENIZ D., TUNCER B. S., KILIC S., SUKRUOGLU O., ALTUNDAG K., KILIÇ L., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.285, (Full Text) Sustainable Development

Epitelya Over Kanserli Hastalarda Serum İnsulin-Like Growth Factor (IGF-1) ve İnSulin- Like Growth Factor Binding Protein-3'ün Klinik Önemi

Tastekin D., Karabulut S., Tas F., Ciftci R., TİLGEN YASASEVER C., DURANYILDIZ H. D.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.571, (Full Text) Sustainable Development

Platin dirençli nüks eden baş boyun tümörlerinde setuximabın rolü, olgu değerlendirmesi

Karabulut S., Ekenel M., Tambaş M., Taştekin D., Altun M., Meral R., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.363, (Full Text)

Küçük hücreli dışı akciğer kanserli hastalarda anjijenik markırların prognostik ve prediktif rolü

KESKİN S., KILIC L., YILDIZ I., ÇİFTÇİ R., KARABULUT S., ŞEN F., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 March 2014 - 23 April 2013, pp.333, (Full Text) Sustainable Development

Meme Kanserli Hastalarda Serum Par-1 (Protease Activated Receptor-1) Düzeylerinin Klinik Açıdan Önemi

Ciftci R., Karabulut S., Aksit E., TAŞ F., TİLGEN YASASEVER C., VATANSEVER S., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.500, (Full Text) Sustainable Development

Serum Makrofaj Migrasyon İnhibitör Faktörü (MIF) Düzeylerinin Epitelyal Over Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü

Karabulut S., Ciftci R., Tastekin D., Vatansever S., Keskin S., Yildiz I., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.420, (Full Text) Sustainable Development

Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma

Karabulut S., Aykan N. F., Yildiz I., Kilic L., Sen F., Vatansever S.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32, (Summary Text)

Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.

Ciftci R., Keskin S., Karabulut S., Yildiz I., Kilic L., Sen F., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)

Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.

Karabulut S., Kilic L., Ciftci R., Yildiz I., Sen F., Keskin S., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text) Sustainable Development

Rezektabl desmoid tümörlerde pozitif cerrahi sınırın ve postoperatif radyoterapinin klinik önemi

KARABULUT S., KESKİN S., EKENEL M., ÇİFTÇİ R., BAŞARAN M., AĞAOĞLU F., et al.

20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.274, (Full Text)

YENİ TANI ALMIŞ MEME KANSERİ OLGULARINDA EVRELEME AMAÇLI PET-BT SONUÇLARIMIZ

ERTEK F., Işık E. G., Şanlı Y., Karanlık H., KESKİN S., KARABULUT S., et al.

25. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 1 - 04 April 2013, pp.53, (Summary Text) Sustainable Development

Noncutaneous melanoma have distinct features from each other and cutaneous melanoma

KESKİN S., EKENEL M., YILDIZ İ., KILIÇ L., KARABULUT S., ŞEN F., et al.

2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011, (Full Text)

Predictive significance of marker half life during chemotherapy in relapsed and non relapsed patients with non seminomatous germ cell testicular tumors

KESKİN S., EKENEL M., KARABULUT S., BAŞARAN M., BAVBEK S.

2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011, (Full Text)

Ekzojen ghrelinin karaciğerde obestatin ve apoptotik değişiklikler üzerine etkileri

Karabulut S., Koyutük M., Bolkent Ş., Saçan Ö., Türk N., Yanardağ R., et al.

XII. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 1 - 04 October 2011, (Full Text)

Meme kanseri hastalarında yeniden evrelendirme amaçlı PET-BT'nin rolü

KUYUMCU S., KARAGÖZ F., ŞANLI Y., EKENEL M., YILDIZ İ., KARABULUT S., et al.

19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.423, (Full Text) Sustainable Development

Books

Kanser Gelişen Fankoni Anemi Hastalarında Kemoterapi Modifikasyonları

Karabulut S., Ferhatoğlu F.

in: Türkiye Klinikleri Çocuk Hematolojisi ve Onkolojisi, YALMAN N., Editor, Türkiye Klinikleri Yayınevi, İstanbul, pp.121-126, 2021

Kanserde Tanı ve Tedavi,

Sarı M., Karabulut S.

in: Onkoloji Hemşireliği Kitabı, GÜLBEYAZ CAN, Editor, Nobel Tıp Kitapevi, İstanbul, pp.189-193, 2019

Metrics

Publication

160

Citation (WoS)

786

H-Index (WoS)

Citation (Scopus)

882

H-Index (Scopus)

Citation (Scholar)

741

H-Index (Scholar)

Project

Open Access

UN Sustainable Development Goals

Publications & Works